Where is the evidence base for benefits of sentinel node biopsy in melanoma

BMJ (Online)

Volumn 346, Issue 7894, 2013, Pages

  Thomas, J Meirion ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; DISEASE CONTROL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; LETTER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MELANOMA; PRIORITY JOURNAL; PUBLICATION; SENTINEL LYMPH NODE BIOPSY; UNITED STATES;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY;

EID: 84873687565     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f675     Document Type: Letter

References (5)

1. Morton DL Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, et al; MSLT Group. Sentinel node biopsy or observation in melanoma. N Engl J Med 2006;355:1307-17.
2. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg 2003;238:538-49.
3. Thomas JM. Concerns relating to the conduct and statistical analysis of MSLT-1. J Plast Reconstr Aesthet Surg 2009;62:442-6
4. Wong SL. Sentinel lymph node biopsy for melanoma: ASCO and SSO joint clinical practice guidelines. Ann Surg Oncol 2012;19:3313-24.
5. Torjesen I. Sentinel node biopsy for melanoma: unnecessary treatment? BMJ 2013;346:e8645. (8 January.)